CXCR4 is highly expressed on malignant cells in MPN, while CXCL12 is abundantly secreted by BM stromal cells, making this axis a promising target for disrupting pathological cell-matrix interactions [17]. Here, CXCL12 is linked to myeloproliferative disorder.